Thomas Choudary Putti Selected Research

Core Binding Factor Alpha 3 Subunit

10/2010	Lack of RUNX3 inactivation in columnar cell lesions of breast.
1/2009	RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
7/2006	RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Choudary Putti Research Topics

Disease

14	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2003
11	Neoplasms (Cancer) 09/2020 - 01/2003
3	Noninfiltrating Intraductal Carcinoma (DCIS) 10/2010 - 11/2002
2	Genomic Instability 05/2011 - 12/2008
2	Ductal Carcinoma 10/2010 - 01/2009
1	Pathologic Complete Response 01/2019
1	Carcinogenesis 09/2018
1	Triple Negative Breast Neoplasms 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2016
1	Hypersensitivity (Allergy) 11/2015
1	Adenocarcinoma 06/2012
1	Hyperplasia 10/2010
1	Papillary Thyroid Cancer 12/2007
1	Necrosis 11/2002

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 10/2010 - 01/2003
4	Estrogen ReceptorsIBA 09/2018 - 01/2003
4	Progesterone Receptors (Progesterone Receptor)IBA 12/2008 - 11/2002
3	Core Binding Factor Alpha 3 SubunitIBA 10/2010 - 07/2006
2	LipidsIBA 09/2020 - 02/2020
2	Trastuzumab (Herceptin)FDA Link 01/2019 - 04/2003
2	Carrier Proteins (Binding Protein)IBA 01/2019 - 09/2018
2	Pharmaceutical PreparationsIBA 09/2018 - 05/2014
2	Progesterone FDA LinkGeneric 01/2018 - 12/2008
2	Estrogens (Estrogen)FDA Link 01/2018 - 12/2008
2	DNA (Deoxyribonucleic Acid)IBA 09/2016 - 01/2009
2	Biomarkers (Surrogate Marker)IBA 01/2016 - 01/2003
2	Transcription Factors (Transcription Factor)IBA 11/2015 - 07/2006
2	Messenger RNA (mRNA)IBA 12/2008 - 07/2006
1	Hemoglobins (Hemoglobin)IBA 09/2020
1	Cyclin DIBA 01/2019
1	Oncogene Proteins (Oncogene Protein)IBA 09/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2016
1	Deoxyribonuclease I (Nickase)IBA 11/2015
1	Superoxide DismutaseIBA 05/2014
1	LigandsIBA 05/2014
1	PPAR gammaIBA 05/2014
1	Prostate-Specific Antigen (Semenogelase)IBA 06/2012
1	Indicators and Reagents (Reagents)IBA 05/2011
1	ParaffinIBA 01/2009
1	Monoclonal AntibodiesIBA 01/2009
1	Formaldehyde (Formol)FDA Link 01/2009
1	TankyrasesIBA 12/2008
1	Biological ProductsIBA 07/2006
1	matrigelIBA 07/2006
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 09/2004
1	Protein Isoforms (Isoforms)IBA 09/2004
1	Mitogen-Activated Protein KinasesIBA 09/2004
1	Tumor Biomarkers (Tumor Markers)IBA 09/2004
1	Hormones (Hormone)IBA 11/2002

Therapy/Procedure

5	Therapeutics 09/2018 - 11/2002
2	Segmental Mastectomy (Lumpectomy) 02/2020 - 12/2018
2	Drug Therapy (Chemotherapy) 01/2019 - 01/2016
1	Neoadjuvant Therapy 01/2019
1	Lasers (Laser) 12/2007